# Strategies to Navigate Expanded Access (Compassionate Use) in Treating Pediatric Oncology

Page: https://stenobird.com/podcast/treating-blood-cancers-14318/strategies-to-navigate-expanded-access-compassionate-use-in-treating-pediatric-oncology
Text version: https://stenobird.com/podcast/treating-blood-cancers-14318/strategies-to-navigate-expanded-access-compassionate-use-in-treating-pediatric-oncology.md
Podcast: [Treating Blood Cancers](https://stenobird.com/podcast/treating-blood-cancers-14318)
Published: 2026-03-03T23:15:00+00:00
Episode link: https://treatingbloodcancers.org/e115/?utm_source=rss&utm_medium=rss&utm_campaign=e115
Audio file: https://media.blubrry.com/treating_blood_cancers/content.blubrry.com/treating_blood_cancers/TBC_E115-Dr_Kutny_Julie_Kelly-Compassion_mixdown_Production.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/treating-blood-cancers-14318/episodes/strategies-to-navigate-expanded-access-compassionate-use-in-treating-pediatric-oncology
Duration seconds: 2395

## Resource

Matthew Kutny, MD, University of Alabama, Birmingham, AL, Julie Guillot, Pediatric AML parent, global advocate, and Blood Cancer United Volunteer, and Kelly Laschinger, MSN, RN, CPNP, CPHON, Blood Cancer United, Washington, DC Recorded on February 19, 2026 Matthew Kutny, MD Professor of Pediatrics Director, Leukemia, Lymphoma and Histiocytosis Program Director, Pediatric Clinical Trials Office Institutional Principal Investigator, Children’s Oncology Group (NCI NCTN) Pediatric Hematology and Oncology University of Alabama at Birmingham Birmingham, AL Julie Guillot Pediatric AML parent, global advocate, and Blood Cancer United Volunteer Kelly Laschinger, MSN, RN, CPNP, CPHON Director, Clinical Trial Support Center Blood Cancer United Washington, DC In this episode, Dr. Matthew Kutny from the University of Alabama, and Kelly Laschinger, CPNP and Julie Guillot from Blood Cancer United, break down what clinicians and families need to know about Expanded Access (EA), also known as Compassionate Use, in treating pediatric oncology patients. They clarify key terms, outline when EA should be considered, and walk through how the process works in real-world practice. Their conversation also addresses common barriers, from institutional requirements to sponsor approval, and highlights how pediatric care teams and advocates can work together to navigate them. Tune in for an informative and insightful conversation to help healthcare professionals better understand and utilize Expanded Access! Blood Cancer United Resources: Clinical Trial Support Center Information Resource Center Dare to Dream Project Ped iatric  A cute  L eukemia Master Clinical Trial ( PedAL ) Mentioned on this episode: Project Facilitate This episode is supported by the Tom Reich Educational Endowment…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/treating-blood-cancers-14318/episodes/strategies-to-navigate-expanded-access-compassionate-use-in-treating-pediatric-oncology/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/treating-blood-cancers-14318/strategies-to-navigate-expanded-access-compassionate-use-in-treating-pediatric-oncology.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.